Emerging personalized approaches for the management of advanced urothelial carcinoma

被引：0

作者：

Tsao, Che-Kai ^{[1
]}

Gartrell, Benjamin A. ^{[1
]}

Oh, William K. ^{[1
]}

Galsky, Matthew D. ^{[1
]}

机构：

[1] Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2012年 / 12卷 / 12期

关键词：

biomarker; bladder cancer; chemotherapy; neoadjuvant therapy; personalized medicine; urothelial carcinoma; INVASIVE BLADDER-CANCER; TRANSITIONAL-CELL-CARCINOMA; GROWTH-FACTOR RECEPTOR; MESSENGER-RNA LEVELS; LUNG-CANCER; RADICAL CYSTECTOMY; NEOADJUVANT CHEMOTHERAPY; GENE-EXPRESSION; PHASE-III; ERCC1; EXPRESSION;

D O I：

10.1586/ERA.12.141

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma, differences in biology and outcomes exist not only among these clinical states but also within each state. Personalized medicine, also commonly referred to as individualized or stratified medicine, offers the potential to optimize treatment for a given patient, based on the ability to accurately predict prognosis, response to treatment and tolerability of treatment. This review will discuss recent efforts, current challenges and future opportunities, for the personalized management of urothelial carcinoma.

引用

页码：1537 / 1543

页数：7

共 47 条

[1] Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer [J].

Als, Anne B. ;

Dyrskjot, Lars ;

von der Maase, Hans ;

Koed, Karen ;

Mansilla, Francisco ;

Toldbod, Helle E. ;

Jensen, Jens L. ;

Ulhoi, Benedicte P. ;

Sengelov, Lisa ;

Jensen, Klaus M. E. ;

Orntoft, Torben F. .

CLINICAL CANCER RESEARCH, 2007, 13 (15) :4407-4414

[2] Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy [J].

Bellmunt, J. ;

Paz-Ares, L. ;

Cuello, M. ;

Cecere, F. L. ;

Albiol, S. ;

Guillem, V. ;

Gallardo, E. ;

Carles, J. ;

Mendez, P. ;

de la Cruz, J. J. ;

Taron, M. ;

Rosell, R. ;

Baselga, J. .

ANNALS OF ONCOLOGY, 2007, 18 (03) :522-528

[3]

Bellmunt J, 2007, P AM SOC CLIN ONCOL, V25

[4] Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial [J].

Black, Peter C. ;

Dinney, Colin P. N. .

CANCER AND METASTASIS REVIEWS, 2007, 26 (3-4) :623-634

[5] Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer [J].

Bochner, Bernard H. ;

Dalbagni, Guido ;

Kattan, Michael W. ;

Fearn, Paul ;

Vora, Kinjal ;

Seo, Hee Song ;

Zoref, Lauren ;

Abol-Enein, Hassan ;

Ghoneim, Mohamed A. ;

Bochner, Bernard H. ;

Dalbagni, Guido ;

Scardino, Peter T. ;

Bajorin, Dean ;

Skinner, Donald G. ;

Stein, John P. ;

Miranda, Gus ;

Gschwend, Juergen E. ;

Volkmer, Bjoern G. ;

Hautmann, Richard E. ;

Chang, Sam ;

Cookson, Michael ;

Smith, Joseph A. ;

Thalman, George ;

Studer, Urs E. ;

Lee, Cheryl T. ;

Montie, James ;

Wood, David ;

Puigvert, Fundacio ;

Palou, Juan ;

Fradet, Yyes ;

LaCombe, Louis ;

Simard, Pierre ;

Schoenberg, Mark P. ;

Lerner, Seth ;

Vazina, Amnon ;

Bassi, PierFrancesco ;

Murai, Masaru ;

Kikuchi, Eiji .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) :3967-3972

[6]

Britten RA, 2000, INT J CANCER, V89, P453, DOI 10.1002/1097-0215(20000920)89:5<453::AID-IJC9>3.0.CO

[7]

2-E

[8] Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma - An immunohistochemical study [J].

Chow, NH ;

Liu, HS ;

Yang, HB ;

Chan, SH ;

Su, IJ .

VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY, 1997, 430 (06) :461-466

[9]

Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0

[10] MESSENGER-RNA LEVELS OF XPAC AND ERCC1 IN OVARIAN-CANCER TISSUE CORRELATE WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY [J].

DABHOLKAR, M ;

VIONNET, J ;

BOSTICKBRUTON, F ;

YU, JJ ;

REED, E .

JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (02) :703-708

← 1 2 3 4 5 →